Symptomatic management of multiple sclerosis

CONTINUUM Lifelong Learning in Neurology

Volumn 13, Issue 5 MULTIPL.SCLEROSIS, 2007, Pages 181-197

  Schwid, Steven R ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BACLOFEN; BENZODIAZEPINE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DANTROLENE; DARIFENACIN; DESMOPRESSIN; DIAZEPAM; DRONABINOL; DULOXETINE; GABAPENTIN; GLATIRAMER; HYOSCYAMINE; ISONIAZID; NARCOTIC ANALGESIC AGENT; ONDANSETRON; OXYBUTYNIN; PREGABALIN; PRIMIDONE; PROPRANOLOL; QUINIDINE; SOLIFENACIN; TIZANIDINE; TOLTERODINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ADULT; BLADDER DISEASE; BRAIN DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COLON DISEASE; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; EDEMA; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; HYPOTENSION; LIVER TOXICITY; MOOD DISORDER; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SPASTICITY; TREMOR; WEAKNESS; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 35148833088     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000293645.20988.3c     Document Type: Review

References (48)

1. ▶ Andrews KL, Husmann DA. Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc 1997;72(12):1176-1183. A review of diagnostic and therapeutic strategies for bladder symptoms related to multiple sclerosis (MS).
2. ▶ Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988;15(1):15-19. A randomized, blinded, crossover study of baclofen and tizanidine in 66 patients with MS demonstrating similar effects on spasticity but more weakness caused by baclofen.
3. ▶ Benedict RH, Cox D, Thompson LL, et al. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004;10(6):675-678. A consensus report recommending a standardized battery of neuropsychological tests for assessing cognition in patients with MS.
4. ▶ Bittar RG, Hyam J, Nandi D, et al. Thalamotomy versus thalamic stimulation for multiple sclerosis tremor. J Clin Neurosci 2005;12(6):638-642. An observational study of thalamotomy versus thalamic stimulation in 20 patients with intractable tremor from MS. Thalamotomy produced greater reduction in tremor but was associated with significant new neurologic deficits.
5. ▶ Carone DA, Benedict RH, Munschauer FE, et al. Interpreting patient/informant discrepancies of reported cognitive symptoms in MS. J Int Neuropsychol Soc 2005;11(5):574-583. A cross-sectional study of 122 patients with MS demonstrating substantial discrepancies between patient and informant reports of cognitive impairment.
6. ▶ Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004;28:140-175. A systematic review of the evidence supporting the safety and efficacy of skeletal muscle relaxants for spasticity and musculoskeletal conditions.
7. ▶ Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006;67(4):652-659. A prospective observational study of 60 patients with relapsing MS showing a significant association between systemic infections and risk of MS relapse, increased MRI activity, and T-cell activation.
8. ▶ Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81(2):164-169. A randomized placebo-controlled crossover study of gabapentin in 22 patients with MS demonstrating improvements in spasticity without negative effects on cognition.
9. ▶ DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003;63(2):153-166. An overview of potential treatments for bladder, bowel, and sexual symptoms in patients with MS.
10. ▶ Di Fabio RP, Soderberg J, Choi T, et al. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil 1998;79(2):141-146. A randomized wait-list controlled study of multidisciplinary outpatient rehabilitation in 46 patients with MS demonstrating reductions in fatigue and other symptoms but no change in functional abilities.
11. ▶ Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970;33(4):528-531. A case series describing benefits of carbamazepine for various paroxysmal sensory and motor symptoms in patients with MS.
12. ▶ Fischer JS, Priore RL, Jacobs LD, et al, and Multiple Sclerosis Collaborative Research Group. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol 2000;48(6):885-892. A randomized placebo-controlled study of interferon beta-1a in 166 patients with relapsing MS demonstrating improvements in information processing and learning/memory in the active treatment group.
13. ▶ Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62(7):1105-1109. A randomized placebo-controlled crossover study of an oral cannabis extract on tremor in 14 patients with MS. None of the objective measures improved with active treatment.
14. ▶ Freeman JA, Langdon DW, Hobart JC, Thompson AJ. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 1997;42(2):236-244. A randomized wait-list controlled study of multidisciplinary inpatient rehabilitation in 66 patients with progressive MS. Impairment did not change, but disability and handicap were alleviated.
15. ▶ Gallien P, Reymann JM, Amarenco G, et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry 2005;76(12):1670-1676. A randomized placebo-controlled study of botulinum toxin for bladder symptoms in 86 patients with MS demonstrating improved larger voids in actively treated patients but no difference in postvoid residual bladder volumes.
16. ▶ Gbadamosi J, Buhmann C, Moench A, Heesen C. Failure of ondansetron in treating cerebellar tremor in MS patients: an open-label pilot study. Acta Neurol Scand 2001;104(5):308-311. An observational study of ondansetron for tremor in 14 patients with MS. Results failed to confirm benefits noted in a prior placebo-controlled crossover study.
17. ▶ Gillen G. Improving mobility and community access in an adult with ataxia. Am J Occup Ther 2002;56(4):462-466. A single case report illustrating potential improved functional abilities in a patient with tremor from MS.
18. ▶ Hallett M, Lindsey JW, Adelstein BD, Riley PO. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 1985;35(9):1374-1377. A randomized placebo-controlled crossover study of isoniazid for tremor in six patients with MS. Modest benefits were noted using several different assessment methods.
19. ▶ Henkin Y, Herishanu YO. Primidone as a treatment for cerebellar tremor in multiple sclerosis: two case reports. Isr J Med Sci 1989;25(12):720-721. A small case series demonstrating benefits from primidone for MS-related tremor in an open-label setting.
20. ▶ Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005;4(10):643-652. A review of comprehensive rehabilitation methods and evidence for an impact on quality of life.
21. ▶ Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol 1984;41(3):280-281. A randomized placebo-controlled crossover study of propranolol and isoniazid in patients with tremor from MS demonstrating no benefit of either treatment.
22. ▶ Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004;63(9):1579-1585. A randomized placebo-controlled study of donepezil for cognitive impairment in 69 patients with MS demonstrating improvements in verbal learning and memory over 24 weeks.
23. ▶ Lopez del Val LJ, Santos S. [Gabapentin in the treatment of tremor.] Rev Neurol 2003;36(4):322-326. An observational study of add-on gabapentin in 63 patients with tremor of various types. Results were mixed depending on the underlying diagnosis.
24. ▶ Mathiowetz VG, Finlayson ML, Matuska KM, et al. Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler 2005;11(5):592-601. A randomized wait-list controlled study of an energy conservation course in 169 patients with MS-related fatigue demonstrating benefits on fatigue and quality of life scales.
25. ▶ Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001;69(6):942-949. A randomized study comparing sertraline, cognitive-behavioral therapy, and group therapy for depression in 63 patients with MS. Sertraline and cognitive-behavioral therapy were more effective than group therapy.
26. ▶ Oken BS, Flegal K, Zajdel D, et al. Cognition and fatigue in multiple sclerosis: potential effects of medications with central nervous system activity. J Rehabil Res Dev 2006;43(1):83-90. A retrospective study in 70 patients with MS demonstrating associations between fatigue, cognitive impairment, and use of psychoactive medications.
27. ▶ Ozgocmen S, Bulut S, Ilhan N, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 2005;23(4):309-313.
28. ▶ Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006;59(5):780-787. A randomized placebo-controlled trial of dextromethorphan/quinidine in 150 patients with pseudobulbar affect associated with MS demonstrating reductions in pathologic laughing and crying with active treatment.
29. ▶ Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11(2):175-181. A meta-analysis of six previous studies demonstrating an association between interferon beta and depression during the first 6 months of treatment. Depression assessment may have been confounded by typical flulike side effects of interferon.
30. ▶ Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39(4):432-441. A randomized controlled study of exercise in 54 patients with MS demonstrating benefits on aerobic fitness and quality of life without changing impairment.
31. ▶ Prosiegel M, Schelling A, Wagner-Sonntag E. Dysphagia and multiple sclerosis. Int MS J 2004;11(1):22-31. A review describing the evaluation and treatment of dysphagia in patients with MS.
32. ▶ Redelings MD, Lee NE, Sorvillo F. Pressure ulcers: more lethal than we thought? Adv Skin Wound Care 2005;18(7):367-372. A case-control study showing that decubitus ulcers are associated with fatal septic infections and are reported as a cause of thousands of deaths each year in the United States.
33. ▶ Régis J, Metellus P, Hayashi M, et al. Prospective controlled trial of gamma knife surgery for essential trigeminal neuralgia. J Neurosurg 2006;104(6):913-924. An observational study of 100 patients with trigeminal neuralgia treated with radiosurgery demonstrating pain response in 83% and lasting sensory disturbance in 10%.
34. ▶ Romero DV, Treston J, O'Sullivan AL. Raising awareness of pressure ulcer prevention and treatment. Adv Skin Wound Care 2006;19(7):398-405. A review describing treatment options for pressure ulcers.
35. ▶ Ross EL. The evolving role of antiepileptic drugs in treating neuropathic pain. Neurology 2000;55(5 suppl1):41-46. A review of studies demonstrating benefits of first-generation and newer anticonvulsants for neuropathic pain related to central and peripheral neurologic disorders.
36. ▶ Sanson F, Schergna E, Semenzato D, et al. [Therapeutic effects of trazodone in the treatment of tremor. Multicentric double-blind study.] Riv Neurol 1986;56(6):358-364. A randomized placebo-controlled study of trazodone in 47 patients with tremor from various causes. Results were mixed.
37. ▶ Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985;312(23):1480-1482. A randomized placebo-controlled crossover study of amitriptyline for pseudobulbar affect in 12 patients with MS demonstrating benefits distinct from antidepressant effects.
38. ▶ Schwid SR, Covington M, Segal BM, Goodman AD. Fatigue in multiple sclerosis: current understanding and future directions. J Rehabil Res Dev 2002;39(2):211-224. A review of the measurement, mechanisms, and treatment of fatigue in patients with MS.
39. ▶ Schwid SR, Goodman AG, Puzas JE, et al. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996;53(8):753-757. A prospective study of 30 patients with relapsing MS showing that bone density was decreased prior to a corticosteroid pulse and that a single corticosteroid pulse did not reduce bone density in fully ambulatory patients.
40. ▶ Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48(4):817-821. A randomized placebo-controlled crossover study in 10 patients with MS demonstrating that 4-aminopyridine improved quantitative measures of motor function.
41. ▶ Schwid SR, Petrie MD, Murray R, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 2003;60(12):1955-1960. A randomized, multi-phase crossover study of cooling therapy in 84 patients with stable deficits from MS. Modest benefits were noted on quantitative measures of function and fatigue scales.
42. ▶ Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006;29(1):31-48. A review of the evidence supporting the safety and efficacy of botulinum toxin for spasticity.
43. ▶ Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005;64(7):1139-1143. A randomized placebo-controlled study of modafinil in 115 patients with MS-related fatigue demonstrating no benefit of active treatment and failing to confirm a prior less-rigorous study.
44. ▶ Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999;56(3):319-324. A randomized placebo-controlled study of 251 patients with relapsing MS demonstrating improvements in cognition in both active and placebo-treated groups during 2 years of evaluation.
45. ▶ Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005;64(7):1267-1269. A double-blind, randomized, placebo-controlled crossover study of aspirin in 30 patients with fatigue from MS showing treatment-related improvements in self-report measures of fatigue.
46. ▶ Zahavi A, Geertzen JH, Middel B, et al. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004;75(11):1553-1557. A 5-year observational study of 21 patients with MS and other spinal disorders getting intrathecal baclofen via subcutaneous programmable pump. Spasticity improved but disability and perceived health status did not.
47. ▶ Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362(9395):1517- 1526. A randomized placebo-controlled trial of an oral cannabis extract and tetrahydrocannabinol in 630 patients with MS and spasticity. There was no improvement in objective measures, but subjective measures improved in both active treatment groups. Unblinding may have confounded study results.
48. ▶ Zorzon M, Zivadinov R, Bosco A, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler 1999;5(6):418-427. A cross-sectional study of sexual symptoms in patients with MS and controls examining the incidence of specific symptoms as well as relationships with other symptoms.